Latest Update — As of September 10, 2026: The NEC baby formula litigation has moved quickly in the past few weeks. On September 1, 2026, Mead Johnson won the first federal bellwether trial in MDL No. 3026, with the jury returning a defense verdict — the first federal jury verdict in the litigation. That followed two major settlement developments: on August 22, 2026, Abbott agreed to pay roughly $670 million to resolve about 2,000 pending NEC claims, and on August 20, 2026, Abbott separately reached a confidential settlement on the $495 million Missouri verdict it had been appealing. As of September 2026, 847 Similac and Enfamil cases remain pending in the federal MDL before Judge Rebecca Pallmeyer, with additional state court trials still scheduled.
Last updated: September 2026
The baby formula lawsuit is one of the largest mass tort cases heading into 2026, with thousands of families seeking compensation after premature infants developed necrotizing enterocolitis from cow’s milk-based formulas. Abbott Laboratories and Mead Johnson, the makers of Similac and Enfamil, face mounting claims that they failed to warn about the serious risks their products posed to preterm babies.
This article covers everything you need to know about the litigation as it stands in 2026. You’ll find settlement projections, eligibility requirements, trial schedules, and filing steps.
Over 1,000 cases are now consolidated in MDL No. 3026 in the Northern District of Illinois. Bellwether trials have begun shaping the future of this litigation, and early verdicts could set the tone for global settlement talks.
If your premature infant was fed Similac or Enfamil in a NICU and later developed NEC, this guide is for you.
Baby Formula Lawsuit
The baby formula lawsuit refers to ongoing litigation against manufacturers of cow’s milk-based infant formulas that allegedly caused necrotizing enterocolitis in premature babies. These lawsuits are consolidated as a multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois under MDL No. 3026.
The core allegation is straightforward. Abbott Laboratories (Similac) and Mead Johnson/Reckitt Benckiser (Enfamil) knew or should have known that feeding cow’s milk-based products to preterm infants carried elevated NEC risks. Despite published medical research, these companies allegedly chose profits over proper warnings.
| Detail | Info |
|---|---|
| Case Type | Mass Tort / MDL |
| Court | Northern District of Illinois |
| MDL Number | 3026 |
| Presiding Judge | Judge Rebecca Pallmeyer |
| Primary Defendants | Abbott Laboratories, Mead Johnson |
| Primary Products | Similac, Enfamil |
Think of it this way: if a car manufacturer knew the brakes failed in certain conditions but kept selling the car without a warning label, that’s the basic framework here. The formula companies allegedly had the data. They sold the product anyway.
By early 2026, the MDL docket lists well over 1,000 individual cases. New filings continue to arrive every month. The litigation has entered a critical phase as bellwether trials produce results that could drive settlement negotiations.
NEC Baby Formula Lawsuit
The NEC baby formula lawsuit specifically targets the link between cow’s milk-based formulas and necrotizing enterocolitis, a devastating intestinal disease that primarily strikes premature infants. NEC destroys the lining of the intestines and can lead to emergency surgery, permanent disability, or death.
Medical literature has warned about this connection for decades. A 1990 study published in The Lancet found that preterm infants fed formula were six to ten times more likely to develop NEC compared to those fed human breast milk exclusively.
- NEC occurs most often in babies born before 37 weeks
- The condition has a mortality rate between 15% and 30%
- Survivors often face lifelong digestive and developmental issues
- NICU staff frequently administered formula without parental consent or full disclosure of risks
Plaintiffs argue that Abbott and Mead Johnson had access to this research. They claim the companies marketed their products as safe for all infants, including the most vulnerable preterm babies, without proper risk disclosures.
The NEC baby formula lawsuit is not about formula being inherently evil. It’s about companies allegedly hiding known dangers from parents and hospitals that trusted them.
Toxic Baby Formula Lawsuit
The toxic baby formula lawsuit label comes from the allegation that cow’s milk-based formula acts as a harmful substance when fed to premature infants with underdeveloped intestinal systems. While the formula is not “toxic” in the traditional chemical contamination sense, plaintiffs argue it functions as a dangerous product for a specific, identifiable population.
The word “toxic” in these cases describes the biological reaction. When a preterm infant’s immature gut encounters bovine proteins, it can trigger severe inflammation. That inflammation leads to NEC, which can destroy intestinal tissue within hours.
| Term | What It Means in This Lawsuit |
|---|---|
| Toxic | Harmful biological reaction in preterm infants |
| Cow’s milk-based | Formula derived from bovine milk proteins |
| NEC trigger | The formula allegedly initiates intestinal necrosis |
| Failure to warn | Companies did not disclose the known risk |
Several plaintiff attorneys have framed this as a “toxic product” case in court filings. That language resonates with juries because it draws a clear line: the product caused harm, the company knew, and nobody told the parents.
This framing has become common in mass tort advertising as well. Legal marketing firms use “toxic baby formula” as a search-optimized term that captures public attention and drives case inquiries.
Key Takeaway: The baby formula lawsuit centers on the claim that Similac and Enfamil manufacturers knew cow’s milk-based products could cause deadly NEC in preterm infants but failed to provide adequate warnings.
Premature Baby Formula Lawsuit
The premature baby formula lawsuit focuses on the most affected group: infants born before 37 weeks of gestation. These babies have underdeveloped digestive systems that cannot process bovine proteins the way full-term infants can.
Premature infants in NICUs across the country were routinely fed Similac and Enfamil products. In many cases, parents had little or no say in the feeding decisions. Hospital staff relied on manufacturer guidelines that did not adequately warn about NEC risks for preterm babies.
- Babies born at 28 weeks or earlier face the highest NEC risk
- Very low birth weight infants (under 1,500 grams) are especially vulnerable
- NEC typically develops within the first two to six weeks of life
- Symptoms include abdominal swelling, bloody stool, and feeding intolerance
The lawsuits argue that manufacturers had a duty to provide specific warnings for premature infant use. Instead, marketing materials positioned these formulas as nutritionally complete and safe for hospital settings, including NICUs.
For families who watched their preterm baby fight NEC after being fed these formulas, the premature baby formula lawsuit represents a path toward accountability. The emotional weight of these cases is immense. Parents trusted hospitals, and hospitals trusted manufacturers.
Baby Formula Class Action Lawsuit
The baby formula class action lawsuit is a common search term, but here’s the reality: this litigation is not structured as a class action. It is a mass tort, consolidated as a multidistrict litigation.
The distinction matters. In a class action, one lawsuit represents an entire group, and everyone gets roughly the same outcome. In a mass tort, each plaintiff files an individual claim. Each case is evaluated on its own facts, injuries, and damages.
| Feature | Class Action | Mass Tort (MDL) |
|---|---|---|
| Case Structure | One case for all plaintiffs | Individual cases consolidated |
| Payout | Same for everyone | Varies by case |
| Control | Lead plaintiff decides | Each plaintiff has a say |
| Settlement | Group settlement | Individual negotiations possible |
| Current Status | Not applicable here | Active under MDL No. 3026 |
Why does this matter to you? Because in a mass tort, your compensation depends on the specifics of your child’s case. A baby who died from NEC will have a very different claim value than a baby who survived with surgery. The severity of injury, duration of hospital stay, and long-term complications all affect the potential payout.
So when you see “baby formula class action lawsuit” in ads or headlines, know that the technical structure is a mass tort MDL. Your individual story matters in this litigation.
Baby Formula Lawsuit Settlement Amounts 2026
Baby formula lawsuit settlement amounts in 2026 are projected to range from $50,000 to over $5 million per case, depending on the severity of the NEC injury. No global settlement has been reached yet, but bellwether trial results and early negotiation signals provide rough estimates.
Settlement tiers are likely to follow a structure based on injury severity:
| Tier | Injury Level | Estimated Settlement Range |
|---|---|---|
| Tier 1 | NEC diagnosis, treated without surgery | $50,000 to $250,000 |
| Tier 2 | NEC requiring surgery, recovery | $250,000 to $1,000,000 |
| Tier 3 | NEC with permanent injury (short bowel syndrome) | $1,000,000 to $3,000,000 |
| Tier 4 | NEC resulting in death | $3,000,000 to $5,000,000+ |
These numbers come from analysis of similar mass tort settlements and early case valuations reported by plaintiff steering committees. The first bellwether trial verdict in 2024 returned a $495 million judgment against Abbott and Mead Johnson, though that amount will likely be reduced on appeal.
Keep in mind that individual settlements often land far below headline verdict numbers. The bellwether verdicts serve as leverage for negotiations, not as guaranteed payouts. If Abbott and Mead Johnson decide to settle the entire MDL, they’ll likely propose a structured fund with tiered payments based on documented injury levels.
By mid-2026, legal analysts expect clearer settlement parameters as more bellwether cases conclude and both sides assess the cost of continued litigation versus a global deal.
Key Takeaway: Settlement amounts in the baby formula lawsuit vary widely by injury severity, with 2026 projections ranging from $50,000 for treated NEC cases to over $5 million for infant deaths.
Who Qualifies for Baby Formula Lawsuit
You may qualify for the baby formula lawsuit if your premature infant was fed cow’s milk-based formula (Similac or Enfamil) and subsequently developed necrotizing enterocolitis. The eligibility criteria focus on three core elements: prematurity, formula exposure, and NEC diagnosis.
Basic Eligibility Checklist:
- The infant was born prematurely (before 37 weeks gestation)
- The infant was fed Similac or Enfamil formula products in a NICU or hospital
- The infant was diagnosed with NEC
- The NEC diagnosis occurred while the infant was being fed or shortly after being fed cow’s milk-based formula
- The infant required surgery, suffered permanent injury, or died from NEC
Some additional qualifying factors can strengthen a claim:
- Medical records showing the specific formula brand administered
- NICU feeding logs documenting the type and duration of formula use
- Pathology reports confirming NEC
- Surgical records if intestinal resection was performed
Parents, legal guardians, and surviving family members can file claims. In wrongful death cases, the estate of the deceased infant files through a representative.
If your baby was full-term and developed NEC, your case may still be considered, but the strongest claims involve preterm infants. The science connecting formula to NEC is most established in the premature population.
How to File a Baby Formula NEC Claim
Filing a baby formula NEC claim starts with contacting a mass tort attorney who handles NEC cases and providing your child’s medical records. The process is simpler than most people expect, but documentation is everything.
Step-by-step filing process:
- Gather medical records from the NICU, including feeding logs, NEC diagnosis, and surgical reports
- Contact a qualified attorney who handles baby formula NEC cases specifically
- Complete a case intake form with details about the infant’s birth, feeding history, and NEC diagnosis
- Sign a retainer agreement with the attorney (most work on contingency, meaning no upfront cost)
- Your attorney files the complaint in the MDL or in state court, depending on strategy
| Filing Detail | What to Know |
|---|---|
| Cost to File | Most attorneys charge no upfront fees |
| Fee Structure | Contingency (attorney takes a percentage of the settlement) |
| Typical Contingency Rate | 33% to 40% of the recovery |
| Where Filed | MDL No. 3026 in Northern District of Illinois or state court |
| Documents Needed | Birth records, NICU records, feeding logs, NEC diagnosis, surgical records |
The statute of limitations varies by state, so timing matters. Some states allow two years from the date of injury, while others provide longer windows. Many states also toll the statute for minors, meaning the clock may not start until the child reaches adulthood. However, waiting too long risks losing access to evidence and weakening your claim.
If you’re unsure whether you have a case, a consultation with a mass tort attorney can clarify your options quickly and at no cost.
Baby Formula Lawsuit Trial Dates 2026
Baby formula lawsuit trial dates in 2026 are expected to include additional bellwether trials in the MDL as well as state court cases in several jurisdictions. The litigation has moved past initial discovery and into active trial phases.
Projected 2026 Trial Timeline:
| Event | Expected Timing |
|---|---|
| Next MDL bellwether trial(s) | Q1 to Q2 2026 |
| State court trials (Illinois, Missouri, California) | Throughout 2026 |
| Potential global settlement talks | Mid to late 2026 |
| MDL status conferences | Monthly through 2026 |
The first bellwether trial in 2024 resulted in a massive plaintiff verdict. That outcome put enormous pressure on Abbott and Mead Johnson. A second bellwether trial was planned, and additional cases are being prepared for trial readiness in early 2026.
Bellwether trials work like test cases. The court selects a handful of representative cases, tries them, and both sides use the results to gauge what a jury will do. If plaintiffs keep winning big verdicts, defendants face growing pressure to settle. If defendants win a case, it slows momentum.
Judge Rebecca Pallmeyer has pushed the litigation forward at a steady pace. Her case management orders through 2025 suggest she intends to maintain that tempo into 2026, with regular status conferences and firm trial schedules.
State court cases add another layer of pressure. Several plaintiffs have filed independently outside the MDL, and state judges in Illinois, Missouri, and California have set their own trial calendars. These parallel tracks give defendants multiple courtrooms to worry about simultaneously.
Key Takeaway: Bellwether trials and state court cases in 2026 will likely determine whether Abbott and Mead Johnson pursue a global settlement or continue fighting case by case.
Enfamil Similac Lawsuit Update
The Enfamil and Similac lawsuit update for 2026 shows both manufacturers remaining as primary defendants with no sign of voluntary settlement. Abbott Laboratories (Similac) and Mead Johnson/Reckitt Benckiser (Enfamil) continue to deny liability and fight the litigation in court.
Abbott Laboratories (Similac):
- Maintains that its products are safe and properly labeled
- Has appealed the 2024 bellwether verdict
- Continues to sell Similac products without additional NEC warnings for preterm use
- Faces hundreds of individual claims in the MDL
Mead Johnson/Reckitt Benckiser (Enfamil):
- Similarly denies all allegations
- Argues that NEC has multiple causes unrelated to formula
- Points to FDA approval as evidence of product safety
- Co-defendant in the MDL alongside Abbott
Both companies have significant financial resources to sustain long-term litigation. Abbott reported over $40 billion in annual revenue in recent years. Reckitt Benckiser reported over $15 billion. Neither company faces an existential financial threat from this litigation, which means they can afford to wait.
However, the 2024 bellwether verdict rattled both defendants. A nearly half-billion-dollar verdict signals that juries are sympathetic to plaintiffs. If subsequent trials produce similar results, the math shifts. At some point, settling becomes cheaper than fighting.
As of early 2026, neither company has announced settlement talks. But behind-the-scenes negotiations in mass tort cases often happen quietly while public trials proceed. Watch for any announcements after the next round of bellwether verdicts.
Toxic Baby Formula NEC Lawsuit
The toxic baby formula NEC lawsuit combines the product liability and failure-to-warn claims into one legal theory: that cow’s milk-based formula was an unreasonably dangerous product when given to premature infants, and manufacturers knew it.
This legal theory has three prongs:
- Design defect: The formula’s composition is inherently harmful to preterm intestines
- Failure to warn: Manufacturers did not provide adequate warnings about NEC risks for premature infants
- Negligent marketing: Companies actively promoted their products for NICU use despite known risks
The failure-to-warn prong is the strongest. Courts generally allow manufacturers to sell products with known risks, as long as they disclose those risks adequately. The plaintiffs’ argument is that Abbott and Mead Johnson did not include specific warnings about NEC on their labels or in their hospital marketing materials.
| Legal Theory | Plaintiff’s Argument |
|---|---|
| Design Defect | Cow’s milk proteins damage preterm intestines |
| Failure to Warn | No NEC risk disclosure on labels or marketing |
| Negligent Marketing | Products pushed to NICUs without risk info |
| Strict Liability | Product caused harm regardless of intent |
Scientific evidence supporting the NEC-formula connection has grown stronger over time. A 2023 Cochrane review confirmed that exclusive human milk feeding reduces NEC incidence in preterm infants compared to formula feeding. This type of peer-reviewed evidence is central to the plaintiffs’ case.
The toxic baby formula NEC lawsuit label serves both legal and marketing purposes. Attorneys use it to frame the case for juries. Marketing firms use it to attract potential claimants through search engines and advertising.
Baby Formula Lawsuit Mass Tort Case Leads
Baby formula lawsuit mass tort case leads are the potential claimants identified through legal marketing efforts and directed to attorneys for case evaluation. In mass tort litigation, the volume of qualified leads often determines how many cases end up filed and how much pressure defendants face.
A “lead” in this context is a person who responds to an advertisement, fills out a contact form, or calls a phone number after seeing a baby formula lawsuit ad. That lead then goes through an intake process where attorneys determine if the case meets the filing criteria.
How the lead pipeline works:
- Marketing firms run ads targeting parents of premature infants
- Interested people submit their information
- Lead generation companies sell or transfer leads to law firms
- Law firms conduct intake interviews and review medical records
- Qualified cases get filed in the MDL or state court
| Lead Type | Description |
|---|---|
| Raw Lead | Initial contact, unverified |
| Qualified Lead | Basic criteria confirmed (preterm baby, formula use, NEC) |
| Retained Lead | Client signs with an attorney |
| Filed Case | Complaint filed in court |
The cost per qualified baby formula lawsuit lead ranges from $200 to $1,500 depending on the source, competition, and verification level. High-quality leads with confirmed medical records command premium prices.
For claimants, understanding this process matters. If you respond to a baby formula lawsuit ad, know that your information may pass through a lead generation company before reaching an actual attorney. Ask questions about who will handle your case and what firm is representing you.
Key Takeaway: Mass tort case leads are the engine that drives baby formula lawsuit filings, and understanding how the lead pipeline works helps claimants make informed choices about their legal representation.
Baby Formula Lawsuit Legal Marketing
Baby formula lawsuit legal marketing refers to the advertising and outreach efforts used to find and recruit potential plaintiffs for NEC-related claims. This is a billion-dollar industry that operates across television, social media, search engines, and direct outreach.
Legal marketing in mass torts is unlike typical advertising. The stakes are enormous. A single retained client in the baby formula lawsuit could represent a case worth hundreds of thousands of dollars in attorney fees. That financial incentive fuels aggressive marketing spending.
Where baby formula lawsuit ads appear:
- Television commercials (local and national)
- Google search ads for terms like “baby formula lawsuit” and “NEC lawsuit”
- Facebook and Instagram targeted ads
- YouTube pre-roll video ads
- Legal directory websites
- Direct mail to parents of NICU patients
The attorneys who handle these cases often do not run the ads themselves. They contract with legal marketing agencies and lead generation firms. These third-party companies specialize in plaintiff acquisition. They build landing pages, run ad campaigns, and funnel interested people to law firms.
For consumers, this means the first entity you interact with after seeing a baby formula lawsuit ad might not be a law firm at all. It could be a marketing company. That’s not necessarily a problem, but you should always confirm that a licensed attorney is handling your case before signing anything.
Legal marketing spending on baby formula NEC cases has increased significantly since the 2024 bellwether verdict. Big plaintiff verdicts drive more ad spending because they signal potential for large settlements.
Baby Formula Lawsuit Marketing Campaigns
Baby formula lawsuit marketing campaigns are coordinated advertising efforts designed to reach the maximum number of potential claimants in the shortest time. These campaigns combine multiple channels and messaging strategies to identify families affected by NEC.
A typical marketing campaign for this litigation includes:
- Awareness phase: TV commercials and social media ads introducing the lawsuit
- Engagement phase: Search engine ads capturing people actively looking for information
- Conversion phase: Landing pages with intake forms and phone numbers
- Retargeting phase: Follow-up ads shown to people who visited but did not complete intake
| Campaign Element | Purpose |
|---|---|
| TV Commercial | Broad awareness, emotional appeal |
| Google Ads | Capture high-intent searchers |
| Social Media Ads | Target demographics (parents, NICU experience) |
| Landing Page | Collect contact information |
| Retargeting Ads | Re-engage visitors who didn’t convert |
| Email Follow-up | Nurture leads toward case intake |
The messaging in these campaigns typically emphasizes urgency (“time is running out”), authority (“thousands of families are filing”), and empathy (“your baby deserved better”). Effective campaigns pair emotional storytelling with clear eligibility criteria.
Campaign budgets for baby formula lawsuit marketing range from $50,000 to several million dollars per month for large-scale operations. The return on investment depends on how many leads convert into retained, filed cases.
Some campaigns are run by law firms directly. Others are operated by marketing agencies on a cost-per-lead basis. The most sophisticated campaigns use data analytics to target specific demographics, such as parents who interacted with NICU-related content or who live in states with favorable statutes of limitations.
Baby Formula NEC Lawsuit Mass Tort Marketing
Baby formula NEC lawsuit mass tort marketing is the specialized subset of legal advertising focused specifically on recruiting plaintiffs for NEC-related claims within the mass tort framework. This type of marketing differs from general legal advertising because it operates at scale and targets a narrowly defined plaintiff population.
Mass tort marketing for NEC cases requires precise targeting. The ideal claimant profile is specific:
- Parent or guardian of a premature infant
- Child was born in a hospital with a NICU
- Child was fed Similac or Enfamil
- Child developed NEC
- Child required surgery or suffered severe outcomes
Mass tort marketing strategies for NEC cases:
- Geotargeting ads to regions with high NICU populations
- Partnering with NICU parent support groups for awareness (not direct solicitation)
- Creating educational content about NEC and formula risks
- Running Spanish-language campaigns to reach underserved communities
- Using programmatic advertising to reach parents across multiple platforms
| Marketing Metric | Typical Range |
|---|---|
| Cost Per Lead (raw) | $50 to $300 |
| Cost Per Qualified Lead | $200 to $1,500 |
| Cost Per Retained Case | $1,000 to $10,000 |
| Conversion Rate (lead to retained) | 5% to 15% |
| Campaign Duration | Ongoing through litigation |
The ethical boundaries of mass tort marketing are constantly debated. Bar associations regulate attorney advertising, but lead generation companies often operate in gray areas. Some campaigns have been criticized for using fear-based messaging or exaggerating potential payouts.
For potential claimants, the key advice is simple: respond to ads if they seem relevant to your situation, but always verify the law firm’s credentials before sharing personal medical information.
Key Takeaway: Legal marketing campaigns for the baby formula NEC lawsuit operate at massive scale, spending millions to find qualified plaintiffs, and understanding this system helps claimants protect themselves while pursuing legitimate claims.
Baby Formula Lawsuit Mass Tort Marketing Campaign
A baby formula lawsuit mass tort marketing campaign is a fully integrated advertising operation designed to generate case leads at volume for attorneys litigating NEC claims. These campaigns represent the intersection of legal strategy, digital marketing, and data analytics.
The anatomy of a full-scale mass tort marketing campaign looks like this:
Phase 1: Research and Strategy (Weeks 1 to 4)
- Identify target demographics and geographic hotspots
- Develop creative assets (video, display ads, landing pages)
- Set budget allocation across channels
- Establish compliance protocols with bar advertising rules
Phase 2: Launch and Optimization (Weeks 5 to 12)
- Deploy ads across TV, search, social, and programmatic networks
- Monitor lead quality and cost metrics daily
- Adjust targeting and messaging based on performance data
- Scale spending on highest-performing channels
Phase 3: Intake and Qualification (Ongoing)
- Screen incoming leads against medical criteria
- Request and review medical records
- Transfer qualified leads to retaining attorneys
- Track conversion from lead to filed case
| Campaign Phase | Timeline | Key Activity |
|---|---|---|
| Research | Weeks 1 to 4 | Strategy and creative development |
| Launch | Weeks 5 to 12 | Active advertising and optimization |
| Intake | Ongoing | Lead screening and case qualification |
| Scaling | Post-launch | Expand budget on winning channels |
The largest baby formula mass tort marketing campaigns in 2025 and heading into 2026 are spending seven figures monthly. The competitive pressure among law firms and marketing agencies for NEC leads has driven costs upward, especially for Google search ads targeting high-intent keywords.
One often overlooked aspect: the quality of the marketing campaign directly affects the quality of the cases filed. Poorly targeted campaigns flood intake centers with unqualified leads, wasting resources. Well-targeted campaigns deliver claimants whose cases match the MDL criteria, resulting in stronger filings and better outcomes.
For the legal industry, baby formula mass tort marketing campaigns represent both opportunity and responsibility. The families these campaigns reach are often still grieving. Ethical marketing respects that reality while connecting them with attorneys who can help.
Frequently Asked Questions
How much money can I get from the baby formula lawsuit in 2026?
Settlement amounts are projected between $50,000 and $5 million per case.
The exact amount depends on injury severity, from NEC diagnosis without surgery to wrongful death.
No global settlement has been finalized yet, but bellwether verdicts suggest significant payouts are possible.
Who qualifies for the NEC baby formula lawsuit?
You may qualify if your premature infant was fed cow’s milk-based formula and developed NEC.
The strongest cases involve babies born before 37 weeks who were fed Similac or Enfamil in a NICU.
Medical records documenting formula use and NEC diagnosis are required.
Is there a deadline to file a baby formula NEC claim?
Statutes of limitations vary by state, typically ranging from two to six years from the date of injury.
Many states toll the deadline for minors, potentially extending the filing window.
Contacting an attorney promptly ensures you don’t miss your state’s specific deadline.
Is the baby formula lawsuit a class action or a mass tort?
The baby formula lawsuit is a mass tort consolidated as MDL No. 3026, not a class action.
Each plaintiff files an individual case, and payouts vary based on specific injuries and circumstances.
This structure gives families more control over their individual claims than a class action would.
What formula brands are named in the baby formula lawsuit?
Similac (made by Abbott Laboratories) and Enfamil (made by Mead Johnson/Reckitt Benckiser) are the primary brands named.
Specific products include standard infant formulas and human milk fortifiers used in NICUs.
Both companies deny that their products cause NEC in premature infants.
The baby formula lawsuit in 2026 represents a turning point for thousands of families. Bellwether trials and mounting legal pressure could push defendants toward a global settlement this year.
If your premature baby was fed Similac or Enfamil and developed NEC, now is the time to gather your medical records and speak with a qualified attorney.
Stay informed as trial dates approach. The next few months could define the outcome for every family involved.
